Biopharma needs a biggie to avoid a down deal year
M&A picked up in the third quarter but overall 2021 has been quiet on the takeover front.
Mylan gets an injection, administered by Pfizer
The combination of Upjohn and Mylan means that, for a change, Pfizer is getting smaller. But will the company’s new chief executive really be able to resist the urge to…
For Celgene the unthinkable suddenly looks less improbable
Celgene stock falls 9%, suggesting that an activist campaign to derail its takeover by Bristol-Myers Squibb is reaching critical mass.
Japanese biopharma rules mid-cap returns
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
